(AMBS) Amarantus BioScience Holdings, Inc.
Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis.
The company has licensed Eltoprazine, a Phase 2 ready Parkinsons Levadopa induced Dyskinesia.
The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") is a diagnostic blood test for Alzheimer’s disease and is being evaluated as a diagnostic blood test for Traumatic Brain injury and Chronic Traumatic Encephalopathy. (MANF) is a human growth factor that plays a key role in the prevention of apoptosis (cell death). It is being developed for the potential treatment of RP, Parkinson's disease, Wolfram syndrome, diabetes, Alzheimer's disease and traumatic brain injury.
Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders.
The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard").
ESS, previously known as PermaDerm® is being developed to be the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days.
MSPrecise is a groundbreaking advancement for the diagnosis of multiple sclerosis and is anticipated to play a pivotal role given the current high rate of misdiagnosis
MSPrecise is a lab-developed test.
For further information, please visit www.Amarantus.com, or connect with the company in Facebook, Twitter, LinkedIn & Google+
PRESS RELEASES & NEWS ARTICLES
Amarantus Receives Orphan Drug Designation From the US FDA for Eltoprazine in the Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia
February 10, 2016
Amarantus to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
February 9, 2016
Burn Care 3.0: Tissue-Engineered Skin is Regenerative Medicine in Action
February 8, 2016
Amarantus Requests Rare Pediatric Disease Designation from US FDA for MANF in the Treatment of Retinitis Pigmentosa
February 5, 2016
Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS)
February 3, 2016
Amarantus Announces Issuance of Chinese Patent Covering Use of MANF for the Treatment of Parkinson's Disease
Patent issuance will provide intellectual property protection in China for protein therapy, gene therapy and cell therapy applications of MANF
January 29, 2016
Amarantus Announces $1M Investment
January 27, 2016
Amarantus Enters Into Letter of Intent to Merge Diagnostics Business Unit Into Avant Diagnostics
January 19, 2016
Amarantus to Present at ICV Sonoma Event
January 15, 2016
Amarantus to Present at SeeThruEquity First Annual Microcap Healthcare Investor Conference
January 11, 2016
Amarantus Requests Rare Pediatric Disease and Orphan Drug Designations from US FDA for Engineered Skin Substitute in the Treatment of Giant Congenital Melanocytic Nevi
DECEMBER 29, 2015
Amarantus Provides Update on cGMP Manufacturing Validation for the Engineered Skin Substitute (ESS) Program
DECEMBER 22, 2015
Bio-engineering skin to treat severe burns
Amarantus BioScience Holdings, Inc.
655 Montgomery Street
San Francisco, CA 94111
c/o ICS Corporate Services SA
29 quai du Mont Blanc
email@example.com Phone: (415) 688-4484 Fax: (408) 852-4427 Gerald's email address
Gerald@amarantus.com IR Calendar
Jenene Thomas Communications
Throughout my 50+ years in the biopharmaceutical industry, I have seen many programs with great promise, but very few programs that possess the fundamentally groundbreaking scientific potential to modify disease biology inherent in MANF. This vast potential for MANF is what makes today’s announcement personally so exciting for me, as the initiation of IND-enabling studies (which start with initiation of clinical grade manufacturing) has been the rate-limiting step for true product development value creation for MANF not only for the ophthalmology programs, but also the rest of the MANF pipeline.
Dr. Wen commented, "We continue to see very encouraging preclinical data with MANF. I am looking forward to continue further development of MANF in collaboration with Amarantus, as I believe it has the potential to address RP, as well as other ophthalmologic disorders with serious unmet need and improve the quality of life of patients where no viable treatments exist today." More information “We are very pleased with the data generated in RP from Dr. Wen’s lab at University of Miami’s Bascom Palmer Eye Institute, one of the world’s most prestigious ophthalmology research and treatment centers,” said Gerald E. Commissiong, President & CEO of Amarantus BioScience Holdings, Inc. “Given the recent granting of orphan drug designations in both the US and EU, the presentation of this data is very timely as we build momentum for MANF in this devastating orphan indication, as well as continue to further establish the MANF orphan ophthalmology franchise. Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
"We are very pleased to receive orphan drug designation for MANF in RP. This represents an important milestone for the company as well as a significant step forward for our clinical and regulatory strategy," said Gerald E. Commissiong
Most people with RP are legally blind by age 40. It is estimated that the market opportunity for Retinitis Pigmentosa exceeds $10B annually.